NICE OKs More Sovaldi And Olysio Indications, Raising Payment Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has recommended additional indications for Janssen’s Olysio and Gilead’s Sovaldi for hepatitis C, but high costs could result in delayed payments from a cash-strapped NHS.